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Summary 
Background Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of 
advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in 
advanced breast cancer and the ability of ctDNA testing to select patients for mutation-directed therapy.
Methods We did an open-label, multicohort, phase 2a, platform trial of ctDNA testing in 18 UK hospitals. 
Participants were women (aged ≥18 years) with histologically confirmed advanced breast cancer and an Eastern 
Cooperative Oncology Group performance status 0–2. Patients had completed at least one previous line of 
treatment for advanced breast cancer or relapsed within 12 months of neoadjuvant or adjuvant chemotherapy. 
Patients were recruited into four parallel treatment cohorts matched to mutations identified in ctDNA: cohort A 
comprised patients with ESR1 mutations (treated with intramuscular extended-dose fulvestrant 500 mg); cohort B 
comprised patients with HER2 mutations (treated with oral neratinib 240 mg, and if oestrogen receptor-positive 
with intramuscular standard-dose fulvestrant); cohort C comprised patients with AKT1 mutations and oestrogen 
receptor-positive cancer (treated with oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant); and 
cohort D comprised patients with AKT1 mutations and oestrogen receptor-negative cancer or PTEN mutation 
(treated with oral capivasertib 480 mg). Each cohort had a primary endpoint of confirmed objective response rate. 
For cohort A, 13 or more responses among 78 evaluable patients were required to infer activity and three or more 
among 16 were required for cohorts B, C, and D. Recruitment to all cohorts is complete and long-term follow-up 
is ongoing. This trial is registered with ClinicalTrials.gov, NCT03182634; the European Clinical Trials database, 
EudraCT2015-003735-36; and the ISRCTN registry, ISRCTN16945804.
Findings Between Dec 21, 2016, and April 26, 2019, 1051 patients registered for the study, with ctDNA results available 
for 1034 patients. Agreement between ctDNA digital PCR and targeted sequencing was 96–99% (n=800, 
kappa 0·89–0·93). Sensitivity of digital PCR ctDNA testing for mutations identified in tissue sequencing was 
93% (95% CI 83–98) overall and 98% (87–100) with contemporaneous biopsies. In all cohorts, combined median 
follow-up was 14·4 months (IQR 7·0–23·7). Cohorts B and C met or exceeded the target number of responses, with 
five (25% [95% CI 9–49]) of 20 patients in cohort B and four (22% [6–48]) of 18 patients in cohort C having a response. 
Cohorts A and D did not reach the target number of responses, with six (8% [95% CI 3–17]) of 74 in cohort A and 
two (11% [1–33]) of 19 patients in cohort D having a response. The most common grade 3–4 adverse events were 
raised gamma-glutamyltransferase (13 [16%] of 80 patients; cohort A); diarrhoea (four [25%] of 20; cohort B); fatigue 
(four [22%] of 18; cohort C); and rash (five [26%] of 19; cohort D). 17 serious adverse reactions occurred in 11 patients, 
and there was one treatment-related death caused by grade 4 dyspnoea (in cohort C).
Interpretation ctDNA testing offers accurate, rapid genotyping that enables the selection of mutation-directed 
therapies for patients with breast cancer, with sufficient clinical validity for adoption into routine clinical practice. Our 
results demonstrate clinically relevant activity of targeted therapies against rare HER2 and AKT1 mutations, 
confirming these mutations could be targetable for breast cancer treatment.
Funding Cancer Research UK, AstraZeneca, and Puma Biotechnology.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Multiple tumour mutations are potentially targetable 
for advanced breast cancer treatment. Some of these 
mutations are common, such as activating PIK3CA 
muta tions that are targetable with PI3K inhibitors, 
including the recently approved alpelisib.1 Other 
potentially targetable mutations, such as HER2 (also 
known as ERBB2) and AKT1 mutations, are rare genetic 
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events, occurring in approximately 5% of patients with 
advanced breast cancer.2,3 Nonetheless, these mutations 
represent attractive therapeutic opportunities, with 
early-phase studies based on tissue genotyping showing 
high response rates with matched targeted therapies.4,5 
Frequently, mutations in the oestrogen receptor (ESR1), 
HER2, and AKT1 can be acquired in advanced disease, 
even if not detectable in the archival primary tumour.2,6,7 
Therefore, archival primary tumour tissue cannot be 
assumed to be representative of the advanced disease 
genomic profile.
Mutation analysis can be obtained from genomic 
analysis of tissue-based biopsies from metastatic disease; 
however, this process is invasive and potentially limited 
by tumour heterogeneity and temporal tumour evolu-
tion.8,9 In addition, mutations might not be present at the 
time of relapse, and only later develop during treatment 
for advanced cancer, posing a clinical challenge in 
regards to acquisition of longitudinal tissue biopsies. 
Highly sensitive assays have been developed in the past 5 
years to analyse circulating tumour DNA (ctDNA), which 
is released into the plasma in small quantities as cancer 
cells die, providing the opportunity for a scalable, non-
invasive approach to profile tumours for somatic 
mutations.10 Retrospective studies show high agreement 
between ctDNA analysis and tumour tissue-based 
analysis in patients with advanced cancer.11 However, 
previous prospective studies comparing commercially 
available ctDNA assays have shown there might be 
substantial discordance in ctDNA testing results,12,13 
raising concerns over whether ctDNA testing is ready for 
widespread clinical adoption.14
We aimed to assess the clinical validity of ctDNA testing, 
and to investigate the clinical utility of using ctDNA to 
select targeted therapies for patients without previous 
tissue testing.
Methods 
Study design and participants 
plasmaMATCH is a multicohort, open-label, non-
randomised, phase 2a clinical trial platform run across 
18 UK hospitals (appendix p 2). Investigators at UK 
hospitals registered eligible patients with the Institute of 
Cancer Research Clinical Trials and Statistics Unit 
(ICR-CTSU) for ctDNA testing. Those with potentially 
targetable mutations identified in ctDNA testing (ESR1, 
HER2, AKT1, or PTEN) were offered entry into one of 
four parallel treatment cohorts (A–D) according to the 
Research in context
Evidence before this study
We searched PubMed on June 11, 2020, for clinical trials 
published between Jan 1, 2000, and Dec 31, 2019, with the terms 
“circulating tumour DNA”, “cell free DNA”, “plasma DNA”, 
“liquid biopsy”, and “ctDNA”, with no restriction on language, 
and identified 212 results. Circulating tumour DNA (ctDNA) 
analysis in multiple retrospective trials has been shown to 
accurately genotype mutations found in the tumour. ctDNA 
analysis therefore has the potential to transform the selection of 
targeted therapies for patients with advanced cancer. In 2019, 
the TARGET trial reported a potential role for ctDNA testing in 
100 patients with advanced cancers in an early-phase clinical trial 
setting. However, there has been uncertainty about the validity 
of ctDNA testing in routine practice, as there have been few large 
prospective studies to assess the accuracy and utility of ctDNA 
testing. In addition, sensitivity has not been perfect in previous 
retrospective studies, suggesting the potential for false negative 
ctDNA results, and, in routine clinical practice, reflex testing of 
tumour tissue is advised to confirm negative results. In 2018, the 
American Society of Clinical Oncology and College of American 
Pathologists guidelines committee on ctDNA analysis concluded 
that the absence of prospective trials was one of the major 
weaknesses in the evidence for bringing ctDNA testing to routine 
practice, with a need for trials that recruited patients solely on 
the basis of ctDNA testing without tissue testing beforehand.
Added value of this study
plasmaMATCH is, to our knowledge, the first large, prospective, 
multicentre study assessing the feasibility and clinical utility of 
ctDNA analysis to direct therapy in patients with advanced 
breast cancer. We recruited 1051 patients for ctDNA testing, 
from both academic and general hospitals, and tested with 
two orthogonal ctDNA analysis techniques. We found high 
agreement between ctDNA assays, and high sensitivity for 
mutations identified in tissue sequencing, especially with 
contemporaneous biopsies. Patients with rare, potentially 
targetable mutations in HER2 and AKT1 in ctDNA had clinically 
important responses with the HER2 inhibitor neratinib and 
AKT inhibitor capivasertib, respectively, similar to activity seen 
in previous tissue sequencing-directed trials. These findings 
confirm that these mutations are targetable for breast cancer 
therapy, and demonstrate the validity and clinical utility of 
using ctDNA testing to screen patients for rare mutations.
Implications of all the available evidence
These findings show that ctDNA testing for mutations has 
sufficient accuracy for widespread adoption in clinical 
practice, with the assays used. The high sensitivity of 
ctDNA testing for tissue mutations calls into question the 
need for reflex tissue testing for negative ctDNA results, 
within the pretreated metastatic breast cancer patient 
population studied. This study also shows the potential of a 
novel liquid biopsy platform to screen for rare oncogenic 
mutations in breast cancer, and how this approach could 
transform clinical trials with efficient and rapid mutation 
screening.
See Online for appendix
Articles
www.thelancet.com/oncology   Published online September 10, 2020    https://doi.org/10.1016/S1470-2045(20)30444-7 3
mutation identified, with therapies matched to 
mutations. A fifth cohort (E) recruiting patients with 
triple-negative breast cancer with no targetable mutation, 
designated to receive olaparib plus the ATR inhibitor 
AZD6738, is ongoing and will be reported separately. 
Eligible patients were women at least 18 years of age with 
histologically confirmed advanced breast cancer that was 
not suitable for treatment with radical or curative intent, 
who had measurable disease, an Eastern Cooperative 
Oncology Group performance status of 0–2, estimated 
life expectancy of more than 3 months, and were suitable 
for a baseline advanced disease biopsy or had an archival 
advanced disease biopsy available for subsequent 
retrospective sequencing and comparison with ctDNA. 
Patients were required to have had disease progression 
on radiological or clinical assessment at registration 
(with radiological confirmation required before treatment 
cohort entry), and to have completed at least one previous 
line of treatment for advanced breast cancer, or relapsed 
within 12 months of neoadjuvant or adjuvant chemo-
therapy. Patients with HER2-positive breast cancer must 
have had at least two previous lines of HER2-targeted 
therapy in the advanced setting (or one line if no further 
HER2-targeted therapies were available). An approved 
protocol amendment implemented on Feb 19, 2018, after 
515 patients had been recruited, required a maximum of 
two previous lines of chemo therapy, antibody–drug 
conjugate, or immunotherapy. Exclusion criteria for 
ctDNA testing included uncon trolled CNS or cardiac 
disease, ongoing toxicities of grade 1 or higher from 
previous treatments, and malignancies of other types 
within the past 3 years. Cohort-specific eligibility criteria 
are given in the protocol (appendix).
The study was co-sponsored by the Institute of Cancer 
Research and the Royal Marsden National Health Service 
(NHS) Foundation Trust, London, UK, and approved by a 
Research Ethics Committee (16/SC/0271). All participants 
gave written informed consent before registration for 
ctDNA testing, and again before treatment cohort entry. 
Safety and efficacy data were reviewed regularly by an 
independent data monitoring committee. Trial oversight 
was provided by an independent trial steering committee.
Procedures 
ctDNA testing was done with two technologies. Digital 
droplet PCR was done at a central laboratory in the 
National Institute for Health Research Centre for 
Molecular Pathology at the Royal Marsden NHS 
Foundation Trust and Institute of Cancer Research 
prospectively in all patients, for mutations in PIK3CA, 
ESR1, HER2, and AKT1 (appendix p 4). From July 10, 2018 
(after recruitment of 680 patients), prospective testing 
also included error-corrected targeted sequencing with 
Guardant360 (Guardant Health; Redwood City, CA, 
USA) for a panel of 73 genes including PIK3CA, ESR1, 
HER2, AKT1, PTEN, and TP53, with retro spective 
sequencing for previously enrolled patients. For 
comparison with ctDNA results, tumour tissue 
sequencing using advanced disease tissue biopsies was 
done retro spectively for patients who entered a treatment 
cohort (appendix p 5). Testing for PIK3CA mutations was 
included to test the validity of the PIK3CA ctDNA testing, 
but was not used for entry to therapeutic cohorts as 
phase 3 studies of treatments for breast cancer with 
PIK3CA mutations were ongoing when plasmaMATCH 
started recruitment.1 A positive result by either ctDNA 
assay was sufficient for cohort entry. If more than 
one mutation was identified, entry to cohorts B–D took 
preference to cohort A.
Cohort A included individuals with ESR1 mutations; 
they received extended-dose 500 mg fulvestrant 
(a selective oestrogen receptor downregulator) admin-
istered intramuscularly on days 1, 8, and 15 in cycle 1, and 
days 1 and 15 in cycle 2 onwards, on a 28-day cycle. 
Pharmacokinetic analysis samples were collected predose 
on cycles 2–4 and compared with a historical population 
model for standard-dose fulvestrant. In cohort A, as a 
prespecified exploratory analysis, ESR1 mutations were 
determined to be clonally dominant or subclonal, with a 
clonally dominant mutation indicating a summed ESR1 
allele fraction of 50% or greater of maximum allele 
fraction detected in the sample by targeted sequencing to 
correct for variations in the purity of ctDNA in plasma 
DNA (appendix p 5).
Cohort B included individuals with HER2 mutations; 
they received 240 mg neratinib (an irreversible pan-HER 
tyrosine kinase inhibitor) orally once a day on a con-
tinuous schedule. In patients with oestrogen receptor-
positive breast cancer, this treatment was administered 
together with fulvestrant 500 mg intramuscularly at 
standard dosing (days 1 and 15 in cycle 1 and day 1 in 
cycle 2 onwards on a 28-day cycle).
Cohort C included individuals with AKT1 mutations 
and oestrogen receptor-positive breast cancer; they 
received 400 mg capivasertib (selective AKT inhibitor) 
orally twice a day for 4 days on followed by 3 days off 
continuously with fulvestrant 500 mg intramuscularly at 
standard dosing.
Cohort D included individuals with an AKT pathway 
activating mutation (mutations in AKT1 with oestrogen 
receptor-negative breast cancer, or PTEN inactivating 
mutations or homozygous deletion [irrespective of 
oestrogen receptor status]; full criteria are described in 
the appendix p 6). Patients with mutations identified 
in previous tumour sequencing done outside of 
plasmaMATCH were also eligible for this cohort. This 
cohort received 480 mg capivasertib monotherapy orally, 
twice a day for 4 days on, followed by 3 days off, 
continuously.
In addition to the eligibility criteria for ctDNA testing, 
for cohort assignment patients with a relevant targetable 
mutation had to have adequate haematological, renal, and 
hepatic function (adequate defined as absolute neutrophil 
count ≥1·0 × 10⁹ cells per L, platelet count ≥100 × 10⁹ per L, 
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haemoglobin ≥9 g/dL, serum crea tinine ≤1·5 × the upper 
limit of normal [ULN], total bilirubin ≤1·5 × ULN, alanine 
aminotransferase and aspartate aminotransferase 
≤3 × ULN [or ≤5 × ULN in the presence of liver 
metastases]). For cohorts C and D, patients were excluded 
if baseline glycated haemoglobin (HbA1c) was ≥8·0% (64 
mmol/mol) or fasting plasma glucose was ≥7·0 mmol/L 
(126 mg/dL), or they had poorly controlled diabetes. 
Patients were eligible for cohort entry with detection of a 
mutation at any allele fraction, and clonal dominance was 
not considered in eligibility.
Once enrolled into a cohort, treatment was given until 
disease progression, unacceptable toxicity, or pregnancy. 
Participants could also discontinue from trial treatment at 
any time at their own request or be discontinued at 
the discretion of the treating clinician. Within each cohort, 
dose modifications were permitted for patients 
experiencing toxicities related to treatment.
Patients underwent CT or MRI scan and bone scan at 
baseline, with CT or MRI scan repeated every 8 weeks 
until 32 weeks after commencing treatment, and every 
12 weeks thereafter, for disease evaluation using 
Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1 criteria. There was no independent central 
review of disease outcome. Laboratory assessments, 
adverse event recording, and vital signs were performed 
every 4 weeks at a minimum. Toxicity was assessed 
using National Cancer Institute Common Terminology 
Criteria for Adverse Events version 4. Coding was done 
with use of the Medical Dictionary for Regulatory 
Activities version 22.
Outcomes 
The primary endpoint for cohorts A–D was confirmed 
objective response rate defined as a confirmed complete 
response or partial response according to RECIST criteria 
at any point during trial treatment. Secondary endpoints 
included duration of response (defined as time from the 
first documentation of complete response or partial 
response until date of disease progression or last date of 
follow-up), clinical benefit rate (defined as complete 
response, partial response, or stable disease for more 
than 6 months during trial treatment), progression-free 
survival (defined as time from cohort entry to first date of 
either confirmed progression of disease according to 
RECIST criteria or death from any cause), safety and 
tolerability of therapies, frequency of mutations, accuracy 
of ctDNA testing by agreement between ctDNA mutation 
status and tissue mutation status and the proportion 
of patients entering a cohort, and pharmacokinetics 
(for cohorts A and B). Prespecified exploratory endpoints 
included confirmed response rate in clonally dominant 
versus subclonal mutations in cohort A.
Statistical analysis 
All cohorts used a single-stage A’Hern design with α 5%, 
to have 80% power. Cohort A assumed an unacceptable 
response rate of 10% and a target response rate of 20% in 
the final design, requiring 13 or more responses from 
78 evaluable patients to infer activity. This assumption 
was an approved amendment (on May 1, 2018) to the 
original two-stage design to account for the ctDNA testing 
detecting subclonal mutations as well as clonal mutations 
where the response rate was expected to be lower 
(appendix p 6). Cohorts B, C, and D each assumed an 
unacceptable response rate of 5% and a target response 
rate of 25%, requiring three or more responses from 
16 evaluable patients. Over-recruitment into cohorts B, 
C, and D was allowed while ctDNA testing remained 
active. We estimated that 1000 patients would be required 
to enter ctDNA testing to recruit sufficient patients for 
cohorts B and C. This number gave 85% probability of 
identifying 25 patients for a mutation with prevalence of 
3% for each of cohorts B, C, and D individually, allowing 
for 36% attrition between ctDNA screening and cohort 
entry.
Objective response rate, duration of response, and 
clinical benefit rate were measured in an evaluable 
population defined as those patients with measurable 
disease per RECIST at baseline and at least one 
on-treatment assessment; patients who stopped treat-
ment because of intolerable toxicity or death without 
having a scan after baseline were evaluable and recorded 
as non-responders. Proportions and two-sided 95% CIs 
for estimation purposes were reported for each cohort 
and in prespecified subgroup analyses (by clonally 
dominant versus subclonal mutations in cohort A, 
compared using a Fisher’s exact test, by hormone 
receptor status in cohort B, and by AKT1 or PTEN 
mutation in cohort D). Analysis of clonality of HER2 
mutations in cohort B and of AKT1 in cohort C was a 
post-hoc analysis.
In post-hoc exploratory analyses, response rates for 
each cohort were reported by PIK3CA and TP53 mutation 
status and, for cohort A, tissue mutation status. For 
inference purposes, thus corresponding to the design 
characteristics underpinning the trial’s hypothesis testing 
(ie, alpha 5%, one-sided), proportions and two-sided 
90% CIs are reported.
Progression-free survival was measured in the intention-
to-treat population. Kaplan-Meier curves were plotted and 
median progression-free survival is reported with 95% CIs 
for each cohort. Patients who were alive and progression 
free were censored at date of last follow-up; patients who 
had non-RECIST confirmed progression (eg, clinically 
judged progression or radiologically confirmed but lesions 
not measured according to RECIST) were censored at the 
date progression was reported. The safety population 
included all patients who had at least one dose of treatment, 
regardless of their eligibility, and treatment-emergent 
adverse events where more than 10% of patients reported 
any grade of the adverse event or any patients reported the 
adverse event at grade 3 or higher were presented. In 
addition, pharmacokinetics were reported as a percentage 
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change from an approved historical population pharma-
cokinetic model for standard-dosing 500 mg fulvestrant, in 
cohort A only. Pharmacokinetic data for cohort B will be 
reported elsewhere. Safety was assessed on the basis of the 
incidence of adverse events.
Agreement between digital PCR and targeted sequencing 
was assessed with a kappa score and 95% CIs. Comparison 
of ctDNA with retrospective tissue biopsy sequencing was 
reported with sensitivity, specificity, and 95% CIs.
Analyses used a database snapshot taken on 
Nov 6, 2019. Where reported, p values of less than 0·05 
were deemed significant. All analyses were conducted 
using Stata (version 15.1). This study is registered with 
ClinicalTrials.gov, NCT03182634; the European Clinical 
Trials database, EudraCT2015-003735-36; and the 
ISRCTN registry, ISRCTN16945804.
Role of the funding source 
The funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing 
of the report. AstraZeneca and Puma Biotechnology 
reviewed the final version of the report, but had no role in 
the decision to submit the manuscript for publication. 
The corresponding author had full access to all of the data 
and the final responsibility to submit for publication.
Results 
Between Dec 21, 2016, and April 26, 2019, 1051 patients 
were registered into the study (1044 via ctDNA screening, 
seven via previous tumour sequencing; figure 1; 
appendix p 17) with ctDNA results available for 
1034 patients (99·0%). Digital PCR results were available 
for 1025 patients (98·2%) and targeted sequencing results 
were available for 800 patients (76·6%; 364 prospective 
and 436 retrospective). The median time from blood draw 
to ctDNA results was 13 days (IQR 11–15) for digital PCR 
and 10 days (8–11) for sequencing. Patients had a median 
of one (IQR 0–2) previous lines of chemotherapy, and a 
median of two (1–3) previous lines of systemic therapy 
(table).
A somatic mutation was detected in 743 (93%) of 
800 patients with ctDNA targeted sequencing results 
(appendix p 18). ESR1 mutations were found almost 
exclusively in hormone receptor-positive breast cancer, 
were found at lower average allele fractions than other 
mutations, and were frequently polyclonal (appendix 
pp 17–18). HER2 mutations were found least frequently 
in triple-negative breast cancer, while AKT1 mutations 
were found at a similar frequency in hormone receptor-
positive HER2-negative breast cancer and triple-negative 
breast cancer (appendix p 18).
Gene-level agreement for mutation identification 
between ctDNA digital PCR and targeted sequencing 
(n=800) was 96–99% (kappa 0·89–0·93; figure 1). 
Individual mutation agreements were also high 
(appendix p 19). An advanced tissue biopsy was sequenced 
retrospectively for 77 patients who entered a cohort. 
Sensitivity (or percent-positive agreement reflecting the 
absence of gold standard) for digital PCR was 93% 
(95% CI 83–98) overall and 98% (87–100) in patients with 
contemporaneous biopsies (appendix pp 17, 20). By 
contrast, digital PCR sensitivity in patients with time-
discor dant biopsies was 85% (95% CI 66–96; appendix 
p 20). Sensitivity for targeted sequencing was 95% 
(95% CI 87–99) overall and 100% (92–100) in patients with 
contemporaneous biopsies (appendix p 21). Sensi tivity for 
time-discordant biopsises is show in the appendix (p 20). 
Specificity for both digital PCR and sequencing (or 
percent-negative agreement reflecting the absence of gold 
standard) was high for AKT1, HER2, and PIK3CA, varying 
by gene (appendix p 17). ESR1 mutations had lower 
percent-negative agreement.
Mutations were identified in 533 (51·1%) of 
1044 patients registered for ctDNA testing and 
357 (34·5%) of 1034 with results had targetable mutations 
eligible for cohort entry, of whom 136 entered one of 
the five available cohorts. In patients who entered 
cohorts A–D, combined median follow-up was 
14·4 months (IQR 7·0–23·7). The most common reason 
for not entering a cohort was that the patient was 
ineligible based on the specific eligibility criteria for the 
relevant cohort, or in the case of cohort A (ESR1 
mutation), 64 patients did not enter because of cohort A 
being suspended (while the protocol amendment to 
change the design was ongoing) or closed (figure 1; 
appendix p 7).
84 (38%) of 222 patients with an ESR1 mutation in 
ctDNA identified while cohort A was open to recruitment 
were enrolled in cohort A (figure 1, table). The most 
common ESR1 mutations detected in plasma were 
Asp538Gly (45 [54%] of 84), Tyr537Ser (31 [37%]), and 
Glu380Gln (29 [35%]). 74 patients were evaluable for 
response: four patients did not start treatment and six did 
not have on-treatment RECIST-assessable imaging. 
Six (8% [95% CI 3–17]) of 74 patients had a confirmed 
partial response with a median duration of response of 
7·0 months (IQR 3·7–8·3) and four patients continuing 
on treatment at data cutoff (figure 2). The clinical benefit 
rate was 12 (16% [95% CI 9–27]) of 74 patients. 69 (82%) of 
84 patients had a RECIST-confirmed progression event or 
death. Median progression-free survival was 2·2 months 
(95% CI 1·8–3·6; appendix p 22). In a pre-planned 
exploratory analysis, five (12% [95% CI 4–26]) of 
41 patients with clonally dominant ESR1 mutations, and 
none (0% [0–13]) of 27 patients with subclonal mutations 
had a confirmed response (p=0·15; 27 [40%] of 68 ESR1 
mutations were subclonal); six patients had unknown 
clonality. The most common grade 3 or grade 4 adverse 
event was increased gamma-glutamyltransferase 
(13 [16%] of 80 patients; appendix p 9). One patient had a 
serious adverse reaction: grade 3 superior sagital sinus 
thrombosis. There were no treatment-related deaths and 
41 (49%) all-cause deaths reported (38 breast cancer and 
three unknown cause). The main reason for treatment 
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1051 met inclusion criteria and registered for plasmaMATCH
84 entered cohort A
  (ESR1 mutation)
80 initiated 
  treatment
 74 were evaluable 
  for response
21 entered cohort B
  (HER2 mutation)
20 initiated 
  treatment
20 were evaluable 
  for response
18 entered cohort C
  (AKT1 mutation 
  and oestrogen 
  receptor-positive
  breast cancer)
18 initiated
  treatment
18 were evaluable 
  for response
19 entered cohort D
  (AKT basket;
  AKT1 mutation 
  with oestrogen 
  receptor-negative 
  breast cancer, or 
  PTEN mutation)
19 initiated
  treatment
19 were evaluable 
  for response
1 entered Cohort E; 
 to be reported at a
 later date (triple-
 negative breast 
 cancer with no
 mutation)
1044 registered for
 ctDNA testing
10 results not available (test failed or not done)
7 registered to
 cohort D with
 previous tumour
 tissue sequencing
1034 ctDNA testing
 results available*
 1025 digital PCR
 364 targeted
 sequencing
501 with no mutation or amplification identified
533 with mutation
 or amplification
 identified
176 not eligible for cohort 
 148 PIK3CA mutation
 20 HER2 amplification
 8 PIK3CA mutation and HER2 amplification
357 with targetable
 mutation(s)
 identified
136 entered a
 cohort via  
 ctDNA testing
221 did not enter a cohort
 67 ineligible
 22 patient choice
 40 clinician decision
 64 cohort A suspended or closed
 6 other cohort closed (deadline passed for cohort entry)
 8 died before cohort entry
 14 unknown
Figure 1: Trial profile
Further detail on accuracy of 
ctDNA testing is provided in 
the appendix (p 17). 
ctDNA=circulating tumour 
DNA. *436 additional samples 
were analysed by targeted 
sequencing retrospectively; 
these were not used for 
determining cohort suitability; 
agreement between digital 
PCR and targeted sequencing 
(n=800) was as follows: 
AKT1 kappa 0·93 
(95% CI 0·87–0·99), 
HER2 kappa 0.89 (0·79–0·98), 
ESR1 kappa 0·90 (0·86–0·93), 
and PIK3CA kappa 0·92 
(0·89–0·95).
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discontinuation was disease progression (72 [95%] of 
76 patients; appendix p 8). Two patients had reductions of 
fulvestrant dosing frequency. 29 patients did not have a 
day 15 injection given on at least one occasion. Ten delays 
to treatment were reported in nine patients. The median 
relative dose intensity in patients starting treatment was 
100% (IQR 97–100, range 33–104). Pharmacokinetic 
analysis was consistent with elevated fulvestrant exposure 
compared with standard-dosing 500 mg fulvestrant in a 
historical population pharmacokinetic model (appendix 
p 10). Fulvestrant activity was similar in patients with and 
without ESR1 mutations in tissue sequencing (appendix 
p 29).
21 (58%) of 36 patients with an HER2 mutation in 
ctDNA were enrolled in cohort B (figure 1, table). The 
most common HER2 mutations detected in plasma were 
Leu755Ser (ten [48%] of 21 patients), Val777Leu 
(four [19%]), and Ser310Phe (three [14%]). 20 patients were 
evaluable for response, as one patient did not start 
treatment. Five (25% [95% CI 9–49) of 20 patients had a 
confirmed response (one complete and four partial), and 
an additional three patients had unconfirmed partial 
responses (figure 3). Four (25% [95% CI 7–52]) of the 
protocol-specified first 16 evaluable patients had a 
response. One patient had a complete response, ongoing 
at 29 months duration. Median duration of response was 
5·7 months (IQR 3·7–9·7) with three patients continuing 
on treatment at data cutoff. The clinical benefit rate was 
nine (45% [95% CI 23–68]) of 20 patients. 16 (76%) of 
21 patients had a RECIST-confirmed progression event or 
All registered 
patients 
(n=1051)
Patients with ESR1 mutation 
(n=222)
Patients with HER2 
mutation (n=36)
Patients with oestrogen 
receptor-positive breast 
cancer and AKT1 mutation 
(n=30)
Patients with oestrogen 
receptor-negative breast 
cancer and AKT1 mutation 
or PTEN mutation (n=37)
Entered 
cohort A 
(n=84)
Did not enter 
cohort A 
(n=138)
Entered 
cohort B 
(n=21)
Did not enter 
cohort B 
(n=15)
Entered 
cohort C 
(n=18)
Did not enter 
cohort C 
(n=12)
Entered 
cohort D 
(n=19)
Did not enter 
cohort D 
(n=18)
Age group at registration (years)
<50 285 (27·1%) 18 (21·4%) 32 (23·2%) 2 (9·5%) 2 (13·3%) 3 (16·7%) 2 (16·7%) 7 (36·8%) 3 (16·7%)
50–59 348 (33·1%) 36 (42·9%) 48 (34·8%) 9 (42·9%) 3 (20·0%) 7 (38·9%) 3 (25·0%) 7 (36·8%) 11 (61·1%)
60–69 265 (25·2%) 20 (23·8%) 36 (26·1%) 6 (28·6%) 8 (53·3%) 6 (33·3%) 4 (33·3%) 4 (21·1%) 3 (16·7%)
≥70 153 (14·6%) 10 (11·9%) 22 (15·9%) 4 (19·0%) 2 (13·3%) 2 (11·1%) 3 (25·0%) 1 (5·3%) 1 (5·6%)
Metastatic disease present at 
diagnosis
146 (13·9%) 18 (21·4%) 20 (14·5%) 2 (9·5%) 2 (13·3%) 5 (27·8%) 2 (16·7%) 3 (15·8%) 2 (11·1%)
Histological type at tumour diagnosis
Ductal 777 (73·9%) 63 (75·0%) 103 (74·6%) 9 (42·9%) 6 (40·0%) 13 (72·2%) 9 (75·0%) 14 (73·7%) 11 (61·1%)
Lobular 98 (9·3%) 9 (10·7%) 12 (8·7%) 8 (38·1%) 3 (20·0%) 3 (16·7%) 1 (8·3%) 2 (10·5%) 4 (22·2%)
Mixed ductal and lobular 38 (3·6%) 5 (6·0%) 5 (3·6%) 1 (4·8%) 2 (13·3%) 1 (5·6%) 1 (8·3%) 2 (10·5%) 0
Mixed ductal and mucinous 3 (0·3%) 1 (1·2%) 0 0 0 0 0 0 1 (5·6%)
Other invasive 13 (1·2%) 0 2 (1·4%) 0 1 (6·7%) 0 0 0 1 (5·6%)
Ductal carcinoma in situ 2* (0·2%) 1 (1·2%) 1 (0·7%) 0 0 0 0 0 0
Not known or missing 120 (11·4%) 5 (6·0%) 15 (10·9%) 3 (14·3%) 3 (20·0%) 1 (5·6%) 1 (8·3%) 1 (5·3%) 1 (5·6%)
Tumour grade
1 48 (4·6%) 7 (8·3%) 10 (7·2%) 2 (9·5%) 1 (6·7%) 1 (5·6%) 1 (8·3%) 0 0
2 402 (38·2%) 37 (44·0%) 70 (50·7%) 11 (52·4%) 6 (40·0%) 11 (61·1%) 8 (66·7%) 11 (57·9%) 6 (33·3%)
3 445 (42·3%) 28 (33·3%) 44 (31·9%) 4 (19·0%) 5 (33·3%) 5 (27·8%) 1 (8·3%) 6 (31·6%) 12 (66·7%)
Not known or missing 156 (14·8%) 12 (14·3%) 14 (10·1%) 4 (19·0%) 3 (20·0%) 1 (5·6%) 2 (16·7%) 2 (10·5%) 0
Molecular subtype†
HR positive, HER2 negative 676 (64·3%) 80 (95·2%) 125 (90·6%) 17 (81·0%) 9 (60·0%) 16 (88·9%) 9 (75·0%) 13 (68·4%) 10 (55·6%)
HR positive, HER2 positive 65 (6·2%) 3 (3·6%) 0 1 (4·8%) 1 (6·7%) 1 (5·6%) 0 0 0
HR negative, HER2 positive 36 (3·4%) 0 0 2 (9·5%) 2 (13·3%) 0 0 0 1 (5·6%)
Triple-negative breast cancer 179 (17·0%) 0 1 (0·7%) 1 (4·8%) 1 (6·7%) 0 0 6 (31·6%) 5 (27·8%)
HR positive, HER2 unknown 39 (3·7%) 1 (1·2%) 7 (5·1%) 0 1 (6·7%) 1 (5·6%) 3 (25·0%) 0 1 (5·6%)
Other‡ 14 (1·3%) 0 1 (0·7%) 0 1 (6·7%) 0 0 0 1 (5·6%)
Not known or missing 42 (4·0%) 0 4 (2·9%) 0 0 0 0 0 0
Disease sites at diagnosis
Visceral 824 (78·4%) 78 (92·9%) 114 (82·6%) 18 (85·7%) 12 (80·0%) 17 (94·4%) 10 (83·3%) 14 (73·7%) 11 (61·1%)
Soft tissue or nodal 668 (63·6%) 56 (66·7%) 66 (47·8%) 12 (57·1%) 11 (73·3%) 11 (61·1%) 5 (41·7%) 15 (78·9%) 15 (83·3%)
Bone 638 (60·7%) 76 (90·5%) 107 (77·5%) 16 (76·2%) 9 (60·0%) 18 (100·0%) 11 (91·7%) 12 (63·2%) 12 (66·7%)
(Table continues on next page)
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death. Median progression-free survival was 5·4 months 
(95% CI 3·4–9·1; appendix p 23). In the subgroup of 
patients with hormone receptor-positive HER2-negative 
breast cancer treated with neratinib and fulvestrant, 
four (24% [95% CI 7–50]) of 17 patients had a confirmed 
response (figure 3). The single triple-negative patient with 
HER2 mutation did not respond. In a post-hoc analysis, 
three (16%) of 19 HER2 mutations were subclonal 
(appendix p 24). The most common grade 3 or grade 4 
adverse events were diarrhoea (four [20%] of 20 patients) 
and hypertension (three [15%]; appendix p 11). Four serious 
adverse reactions were reported in three patients 
(appendix pp 11–12). There were no treatment-related 
deaths and 13 (62%) all-cause deaths reported (12 breast 
cancer and one unknown cause). The main reason for 
treatment discontinuation was disease progression 
(16 [94%] of 17 patients; appendix p 8). All 17 patients with 
oestrogen receptor-positive breast cancer who started 
treatment received all doses of fulvestrant. Neratinib dose 
was reduced to 160 mg for six (30%) of 20 patients, and 
one of these patients had a further dose reduction to 
120 mg. The median relative dose intensity of patients 
starting treatment was 92% (IQR 84–99; range 59–100) for 
neratinib and 100% (100–100; 96–102) for fulvestrant.
All registered 
patients 
(n=1051)
Patients with ESR1 mutation 
(n=222)
Patients with HER2 
mutation (n=36)
Patients with oestrogen 
receptor-positive breast 
cancer and AKT1 mutation 
(n=30)
Patients with oestrogen 
receptor-negative breast 
cancer and AKT1 mutation 
or PTEN mutation (n=37)
Entered 
cohort A 
(n=84)
Did not enter 
cohort A 
(n=138)
Entered 
cohort B 
(n=21)
Did not enter 
cohort B 
(n=15)
Entered 
cohort C 
(n=18)
Did not enter 
cohort C 
(n=12)
Entered 
cohort D 
(n=19)
Did not enter 
cohort D 
(n=18)
(Continued from previous page)
Treatment received for locally advanced or metastatic disease before study registration
Chemotherapy 728 (69·3%) 55 (65·5%) 88 (63·8%) 18 (85·7%) 10 (66·7%) 15 (83·3%) 8 (66·7%) 12 (63·2%) 9 (50·0%)
1 line 345 (32·8%) 26 (31·0%) 38 (27·5%) 7 (33·3%) 4 (26·7%) 8 (44·4%) 5 (41·7%) 7 (36·8%) 4 (22·2%)
2 lines 201 (19·1%) 13 (15·5%) 27 (19·6%) 9 (42·9%) 3 (20·0%) 3 (16·7%) 3 (25·0%) 4 (21·1%) 3 (16·7%)
>2 lines§ 181 (17·2%) 16 (19·0%) 22 (15·9%) 2 (9·5%) 3 (20·0%) 4 (22·2%) 0 1 (5·3%) 2 (11·1%)
Unknown 1 (0·1%) 0 1 (0·7%) 0 0 0 0 0 0
Endocrine therapy¶ 685 (65·2%) 79 (94·0%) 127 (92·0%) 14 (66·7%) 11 (73·3%) 18 (100·0%) 12 (100·0%) 11 (84·6%) 7 (63·6%)
1 line 323 (30·7%) 34 (40·5%) 45 (32·6%) 3 (14·3%) 3 (20·0%) 9 (50·0%) 8 (66·7%) 8 (61·5%) 3 (27·3%)
2 lines 230 (21·9%) 36 (42·9%) 49 (35·5%) 6 (28·6%) 5 (33·3%) 6 (33·3%) 1 (8·3%) 3 (23·1%) 4 (36·4%)
3 lines 117 (11·1%) 8 (9·5%) 30 (21·7%) 5 (23·8%) 2 (13·3%) 3 (16·7%) 3 (25·0%) 0 0
>3 lines 15 (1·4%) 1 (1·2%) 3 (2·2%) 0 1 (6·7%) 0 0 0 0
Total lines of systemic therapy
0 93 (8·9%) 2 (2·4%) 6 (4·3%) 0 1 (6·7%) 0 0 3 (15·8%) 6 (33·3%)
1 275 (26·2%) 15 (17·9%) 25 (18·1%) 3 (14·3%) 3 (20·0%) 1 (5·6%) 3 (25·0%) 5 (26·3%) 3 (16·7%)
2 243 (23·1%) 23 (27·4%) 30 (21·7%) 4 (19·0%) 3 (20·0%) 6 (33·3%) 2 (16·7%) 5 (26·3%) 5 (27·8%)
3 178 (16·9%) 16 (19·0%) 28 (20·3%) 8 (38·1%) 4 (26·7%) 5 (27·8%) 5 (41·7%) 4 (21·1%) 2 (11·1%)
4 109 (10·4%) 12 (14·3%) 18 (13·0%) 4 (19·0%) 2 (13·3%) 3 (16·7%) 2 (16·7%) 2 (10·5%) 0
5 88 (8·4%) 11 (13·1%) 19 (13·8%) 2 (9·5%) 0 0 0 0 2 (11·1%)
>5 65 (6·2%) 5 (6·0%) 12 (8·7%) 0 2 (13·3%) 3 (16·7%) 0 0 0
Other systemic therapy|| 421 (40·1%) 41 (48·8%) 59 (42·8%) 11 (52·4%) 8 (53·3%) 9 (50·0%) 4 (33·3%) 11 (57·9%) 7 (38·9%)
Anti-HER2 therapy 89 (8·5%) 3 (3·6%) 1 (0·7%) 3 (14·3%) 3 (20·0%) 1 (5·6%) 0 0 0
mTOR inhibitor (everolimus or 
vistusertib)
116 (11·0%) 18 (21·4%) 31 (22·5%) 5 (23·8%) 2 (13·3%) 3 (16·7%) 1 (8·3%) 3 (15·8%) 2 (11·1%)
CDK4/6 inhibitor (palbociclib, 
ribociclib, or abemaciclib)
89 (8·5%) 8 (9·5%) 14 (10·1%) 1 (4·8%) 1 (6·7%) 6 (33·3%) 0 4 (21·1%) 1 (5·6%)
Immunotherapy (atezolizumab 
or pembrolizumab)
20 (1·9%) 0 0 0 0 0 0 0 0
Other 45 (4·3%) 1** (1·2%) 6 (4·3%) 1†† (4·8%) 2 (13·3%) 0 3 (25·0%) 2‡‡ (10·5%) 1 (5·6%)
Data are n (%). HR=hormone receptor (oestrogen or progesterone receptor). *Two patients originally had ductal carcinoma in situ only as their primary diagnosis, but relapsed with invasive advanced cancer. 
†Determined at local hospitals from recurrence biopsy (or primary biopsy if recurrence biopsy unavailable). ‡Other molecular subtypes were: four HR negative, HER2 unknown; nine HR unknown, HER2 negative; 
one HR unknown, HER2 positive. §Study was amended after 515 patients had been recruited to require a maximum of two previous lines of chemotherapy. ¶For patients with oestrogen receptor-negative breast 
cancer and AKT1 mutation or PTEN mutation the denominator is patients with HR-positive disease only (for those who entered cohort D n=13; for those that did not enter cohort D n=11). ||Patients may be 
included in more than one type of systemic therapy, but patients are only included once in each category (eg, if a patient had trastuzumab and pertuzumab they are counted once in the anti-HER2 therapy 
category). **Taselisib. ††Capivasertib. ‡‡Lucitanib (n=1) and olaparib (n=1).
Table: Baseline characteristics 
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18 (60%) of 30 patients with an AKT1 mutation in ctDNA 
and oestrogen receptor-positive cancer were enrolled in 
cohort C (figure 1; table). The most common mutation 
detected was Glu17Lys (17 [94%] of 18 patients), and 
Leu52Arg was detected in one patient (6%). All 18 patients 
were evaluable; four (22% [95% CI 6–48]) patients had a 
confirmed partial response, and an additional four patients 
had unconfirmed partial responses (figure 4A). Three (19% 
[4–46]) of the protocol-specified first 16 evaluable patients 
had a response. Median duration of response was 
7·5 months (IQR 4·1–9·8) with four patients continuing 
on treatment at data cutoff. The clinical benefit rate was 
seven (39% [95% CI 17–64]) of 18 patients. 12 (67%) of 
18 patients had a RECIST-confirmed progression event or 
death. Median progression-free survival was 10·2 months 
(95% CI 3·2–18·2; appendix p 25). In a post-hoc analysis, 
four (23%) of 17 AKT1 mutations (clonality was assessable 
in 17 patients) were subclonal (appendix p 24). The most 
common grade 3 or 4 adverse events were fatigue 
(four [22%] of 18 patients), rash (three [17%]), diarrhoea 
(two [11%]), and hyperglycaemia (two [11%]; appendix 
pp 13–14). Eight serious adverse reactions were reported 
in four patients (appendix p 14). There was one treatment-
related death caused by grade 4 dyspnoea and 
six (33%) breast cancer deaths reported. The main reason 
for treatment discon tinuation was disease progression 
(11 [85%] of 14 patients; appendix p 8). All 18 patients 
received all doses of fulvestrant. Capivasertib dose was 
reduced to 320 mg in seven (39%) of 18 patients, and three 
of these patients had a further reduction to 240 mg. The 
median relative dose intensity was 88% (IQR 70–99, 
range 25–101) for capivasertib and 99% (IQR 97–100, 
range 94–102) for fulvestrant.
19 patients were enrolled in cohort D, 12 following 
ctDNA testing and seven following tumour testing 
(figure 1, table 1). The mutations detected were AKT1 
Glu17Lys (five [26%] of 19 patients), AKT1 Leu52Arg 
(one [5%]), PTEN inactivating mutation (12 [63%]), 
and PTEN homozygous deletion (one [5%]). All 
19 patients were evaluable, and two (11% [95% CI 1–33]) 
patients had a confirmed partial response (figure 4B). 
Two (33%, 95% CI 4–78) of the six patients with 
AKT1 mutations responded, and there were two further 
unconfirmed responses in these patients. None of the 
patients with PTEN genomic alterations responded. 
Two (13% [95% CI 2–38]) of the protocol-specified first 
16 patients responded. Median duration of response 
was 3·9 months (IQR 3·7–4·2) with one patient 
continuing on treatment at data cutoff. Two (11% 
[95% CI 1–33]) of 19 patients had a clinical benefit. 
13 (68%) of 19 patients had a RECIST-confirmed 
progression event or death. Median progression-free 
survival was 3·4 months (95% CI 1·8–5·5; appendix p 26). 
The most common grade 3 or grade 4 adverse events 
were rash (five [26%] of 19 patients), hypertension 
(two [11%]), aminotransferase increase (two [11%]), 
gamma-glutamyltransferase increase (two [11%]), and 
vomiting (two [11%]; appendix p 15). Four serious 
adverse reactions were reported in three patients 
(appendix p 15). There were no treatment-related deaths 
and ten (53%) breast cancer deaths reported. The main 
reason for treatment discon tinuation was disease 
progression (15 [83%] of 17 patients; appendix p 8). 
Capivasertib dose was reduced in five (26%) of 
19 patients (four to 400 mg and one to 320 mg). 
The median relative dose intensity of capivasertib was 
94% (IQR 63–100, range 42–102).
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Figure 2: Extended-dose fulvestrant in ESR1-mutant breast cancer (cohort A)
Waterfall plot of maximum change in tumour size in individual patients with ESR1 mutations in ctDNA treated 
with extended-dose fulvestrant. ctDNA=circulating tumour DNA.
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Figure 3: Neratinib in HER2-mutant breast cancer (cohort B)
Waterfall plot of maximum change in tumour size in individual patients with HER2 mutations in ctDNA treated 
with neratinib alone or neratinib plus fulvestrant. HR=hormone receptor. ctDNA=circulating tumour DNA.
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In post-hoc analyses, the response rates in cohorts A–D 
did not vary by PIK3CA or TP53 co-mutational status 
(appendix pp 27–28).
Discussion 
In this large, prospective trial of ctDNA testing in 
advanced breast cancer, we found that ctDNA testing was 
highly accurate, with high agreement between different 
ctDNA testing techniques, and high sensitivity for 
mutations identified in advanced breast cancer tissue 
biopsies. ctDNA testing identified patients with rare 
targetable mutations and these patients were recruited 
into cohorts that were given targeted therapies (matched 
to mutations) without confirmatory tumour testing, with 
activity comparable to previous studies involving tumour 
tissue testing.4,5 We enrolled more than 1000 patients 
across the UK in less than 3 years, and the dynamic trial 
platform design allowed for the simultaneous evaluation 
of multiple targeted treatment options.
The availability and accuracy of ctDNA testing shown 
in this study compares favourably with tissue-based 
mutation testing. Nearly all patients (99%) received a 
result from ctDNA testing, contrasting with previous 
tumour sequencing studies where results were typically 
received in only 70–90% of patients.15,16 In addition, 
previous tumour sequencing studies generally only 
included patients with disease that could be biopsied, 
which is not a constraint for ctDNA testing. Results were 
received relatively quickly after blood draw, compared 
with results for tissue-based testing, and this led to a 
high conversion rate of patients with ctDNA mutations 
into the corresponding treatment cohort. The accuracy of 
ctDNA testing was also similar to that achieved with 
tissue sequencing.17 Discordance between ctDNA results 
was still observed for patients at low allele frequency 
mutations, suggesting further potential for assay 
development. ESR1 mutations had lower percent-
negative agreement, probably reflecting the subclonality 
of acquired ESR1 mutations, with ctDNA detecting 
mutations present in metastasic sites other than the one 
biopsied. Nevertheless, the degree of sensitivity observed 
in this study suggests that, within the patient population 
of advanced disease patients recruited, ctDNA testing 
could replace tissue-based mutation analysis. However, 
we note that tissue biopsy will remain important for 
immunohistochemistry, and for copy number-based 
assessment. Digital PCR offered similar accuracy to 
sequencing, with substantial cost efficiency, although 
this comparison was limited to the specific mutations 
analysed. The academic clinical laboratory doing the 
digital PCR assay achieved the trial target turnaround 
time of results within 14 days. A shorter turnaround time 
could easily be achieved if required in clinical practice, 
resulting in a cost-efficient method of ctDNA 
analysis. 533 (51·1%) of 1044 patients who under went 
ctDNA testing had a potentially targetable mutation 
(PIK3CA, ESR1, HER2, AKT1, or PTEN), indicating a 
potential value for ctDNA testing.
Our results confirm clinically relevant activity of 
targeted therapies against rare activating mutations in 
breast cancer. In a previous phase 1 study with an 
expansion cohort of those with HER2-mutant breast 
cancer identified in tissue, who were given neratinib, 
there was a 32% unconfirmed response rate after 8 weeks 
of treatment.4 In our study, neratinib for HER2-mutant 
breast cancer identified by ctDNA testing had comparable 
activity to that observed when guided by tissue testing, 
with durable responses. Similarly, capivasertib had high 
–100
Ch
an
ge
  in
 tu
m
ou
r s
ize
 fr
om
 b
as
el
in
e 
(%
)
–80
–60
–40
–20
0
20
40
60
80
100
–100
Ch
an
ge
 in
 tu
m
ou
r s
ize
 fr
om
 b
as
el
in
e 
 (%
)
Patients
–80
–60
–40
–20
0
20
40
60
80
100
A
B
Previous fulvestrant therapy
No previous fulvestrant therapy
AKT1 Glu17Lys
AKT1 Leu52Arg
PTEN single nucleotide variant
PTEN truncating
PTEN deletion
Entered trial on the basis of ctDNA testing
Entered trial on the basis of tissue sequencing
HR positive, HER2 negative
HR negative, HER2 negative
AKT1 Leu52Arg
AKT1 Glu17Lys
Figure 4: Capivasertib in AKT1-mutant and PTEN-mutant breast cancer (cohorts C and D)
(A) Waterfall plot of maximum change in tumour size in individual patients with HR-positive cancer and 
AKT1 mutations in ctDNA, treated with capivasertib plus fulvestrant (cohort C). (B) Waterfall plot of maximum 
change in tumour size in individual patients with AKT1 mutations and HR-negative breast cancer, or with activating 
PTEN mutations, treated with capivasertib (cohort D). ctDNA=circulating tumour DNA. HR=hormone receptor. 
PTEN truncating=PTEN truncating nonsense or frameshift mutation. PTEN deletion=PTEN homozygous deletion.
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activity in patients with ctDNA-identified AKT1 mutations, 
both in hormone receptor-positive cancer with fulvestrant 
and in hormone receptor-negative cancer as a single 
agent, again con firming the results of a previous phase 1 
study.5 These results confirm the high activity of these 
drugs against HER2 and AKT1 mutations, and strongly 
support the need for registration trials, facilitated by a 
ctDNA testing programme.
Our study did not show benefit from increasing the dose 
of fulvestrant in patients with ESR1 mutations in ctDNA. 
Previous research has suggested that fulvestrant at 
standard doses does not maximally inhibit or degrade 
mutated ESR1,18 and we assessed whether more frequent 
administration of fulvestrant would increase therapeutic 
utility. Although exposure was increased in later cycles, 
this was insufficient to enhance activity, with the response 
rate remaining similar to that previously reported.19,20 We 
note however that our study recruited a heavily pretreated 
population, and this might have reduced the activity of 
fulvestrant. More potent oestrogen receptor inhibitors, 
such as novel oral oestrogen receptor degraders and 
modulators, are also likely to be required.21 We found that 
patients with Tyr537Ser ESR1 mutations were no less 
sensitive to fulvestrant than those with other ESR1 
mutations, and that ESR1 mutations were frequently 
subclonal, with detection of ESR1 mutations in ctDNA that 
were not present in contemporaneous single site tissue 
biopsies, reflecting the limited sampling of single site 
tissue biopsies. Fulvestrant activity was similar in patients 
with and without ESR1 mutations in tissue sequencing.
Our study has limitations. Inclusion of relatively heavily 
pretreated patients might reduce activity of the targeted 
drugs, especially in cohort A, and future ctDNA selection 
trials might benefit from more restrictive entry criteria. 
The study was designed to assess the activity of therapies 
against specific genomic events, but it did not target 
PIK3CA mutations,1 and as a result relatively few of the 
patients registered to the trial had a response to therapy 
(17 [1·6%] of 1051 patients). However, mutation-directed 
therapy with alpelisib is now approved to target 
PIK3CA mutations, and our study shows the clinical 
validity of using ctDNA to direct therapy. Cohort D was 
designed as a basket cohort from the outset, to explore the 
activity of capivasertib against different AKT pathway 
activating mutations. Only cohort D allowed entry of 
patients with previous tissue sequencing results, as it was 
anticipated that ctDNA testing alone might not recruit 
sufficient patients. Although we identified low activity of 
capi vasertib in PTEN-mutant cancers when used as a 
single agent, AKT inhibition in combination with 
paclitaxel chemotherapy might be efficacious in PTEN-
mutant cancers.22,23 Capivasertib plus fulvestrant might be 
efficacious in endocrine-resistant oestrogen receptor-
positive breast cancer without mutation selection, as 
shown in the FAKTION trial.24 It is not possible to 
robustly compare plasmaMATCH with FAKTION, as 
patients enrolled in plasmaMATCH had more previous 
lines of treatment, and AKT1 mutations were not assessed 
and would be few in number in FAKTION.24
In conclusion, we show that ctDNA testing, with the 
assays employed in this study, has sufficient accuracy for 
widespread adoption in routine clinical practice to 
identify patients with breast cancer who are suitable for 
licensed targeted therapies, such as PIK3CA-mutant 
breast cancer, with the transformative potential of 
efficient and rapid screening for clinical trials. A high 
proportion of patients with specific targeted mutations 
were able to enrol on the matching treatment cohort, 
with clinically important activity observed with therapies 
matched to AKT1 and HER2 mutations. With mutation-
matching therapy now approved in breast cancer, with 
alpelisib for PIK3CA-mutant disease, ctDNA testing can 
be seen as a standard-of-care test for both common and 
rare targetable genetic events.
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